Fenwick represented Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, in its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share. The aggregate gross proceeds from this offering were expected to be $154 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Passage Bio granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as the joint bookrunning managers for the offering. Wedbush Securities Inc. and Chardan acted as co-managers for the offering. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partners Robert Freedman and Effie Toshav and included associates Ryan Mitteness, Daisy Chen, Derrick Chapman, Adam Conway and law clerk Peter Li.
Fenwick also represented Passage Bio in its initial public offering in February 2020.